更新于：2024-12-04
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2024-12-04
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
261
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
669
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2024-11-01JOURNAL OF NUTRITION
Excess Folic Acid Exposure Increases Uracil Misincorporation into DNA in a Tissue-Specific Manner in a Mouse Model of Reduced Methionine Synthase Expression
Article
作者: Brody, Lawrence C ; Malysheva, Olga V ; Brody, Lawrence C. ; Malysheva, Olga V. ; Field, Martha S ; Field, Martha S. ; Heyden, Katarina E ; MacFarlane, Amanda J ; Heyden, Katarina E. ; MacFarlane, Amanda J.
BACKGROUND:
Folate and vitamin B12 (B12) are cofactors in folate-mediated 1-carbon metabolism (FOCM), a metabolic network that supports synthesis of nucleotides (including thymidylate [dTMP]) and methionine. FOCM impairments such as a deficiency or imbalance of cofactors can perturb dTMP synthesis, causing uracil misincorporation into DNA.
OBJECTIVE:
The purpose of this study was to determine how reduced expression of the B12-dependent enzyme methionine synthase (MTR) and excess dietary folic acid interact to affect folate distribution and markers of genome stability in mouse tissues.
METHODS:
Heterozygous Mtr knockout mice (Mtr+/-) model the FOCM-specific effects of B12 deficiency. Folate accumulation and vitamer distribution, genomic uracil concentrations, and phosphorylated histone H2AX (γH2AX) immunostaining were measured in male Mtr+/+ and Mtr+/- mice weaned to either a folate-sufficient control (C) diet (2 mg/kg folic acid) or a high folic acid (HFA) diet (20 mg/kg folic acid) for 7 wk.
RESULTS:
Exposure to the HFA diet led to tissue-specific patterns of folate accumulation, with plasma, colon, kidney, and skeletal muscle exhibiting increased folate concentrations compared with control. Liver total folate did not differ. Although unmetabolized folic acid (UMFA) increased 10-fold in mouse plasma with HFA diet, UMFA accounted for <0.2% of total folate in liver and colon tissue. Exposure to HFA diet resulted in a shift in folate distribution in colon tissue with higher 5-methyl-THF and lower formyl-THF than in control mice. Mtr heterozygosity did not impact folate accumulation or distribution in any tissue. Mice on HFA diet exhibited higher uracil in genomic DNA and γH2AX foci in colon. Similar differences were not seen in liver.
CONCLUSIONS:
This study demonstrates that folic acid, even when consumed at high doses, does not meaningfully accumulate in mouse tissues, although high-dose folic acid shifts folate distribution and increases uracil accumulation in genomic DNA in colon tissue.
2024-10-01PHARMACEUTICAL RESEARCH
Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques
Article
作者: Price, Robert ; Newman, Bryan ; Mangal, Sharad ; Ganley, William J. ; Bielski, Elizabeth ; Conti, Denise S. ; Farias, Gonçalo ; Shur, Jagdeep ; Ganley, William J ; Conti, Denise S
Abstract:
Purpose:
For locally-acting dry powder inhalers (DPIs), developing novel analytical tools that are able to evaluate the state of aggregation may provide a better understanding of the impact of material properties and processing parameters on the invivo performance. This study explored the utility of the Morphologically-Directed Raman Spectroscopy (MDRS) and dissolution as orthogonal techniques to assess microstructural equivalence of the aerosolized dose of DPIs collected with an aerosol collection device.
Methods:
Commercial DPIs containing different strengths of Fluticasone Propionate (FP) and Salmeterol Xinafoate (SX) as monotherapy and combination products were sourced from different regions. These inhalers were compared with aerodynamic particle size distribution (APSD), dissolution, and MDRS studies.
Results:
APSD testing alone might not be able to explain differences reported elsewhere in invivo studies of commercial FP/SX drug products with different Advair® strengths and/or batches. Dissolution studies demonstrated different dissolution rates between Seretide™ 100/50 and Advair® 100/50, whereas Flixotide™ 100 and Flovent® 100 had similar dissolution rates between each other. These differences in dissolution profiles were supported by MDRS results: the dissolution rate is increased if the fraction of FP associated with high soluble components is increased. Principle component analysis was used to identify the agglomerate classes that better discriminate different products.
Conclusions:
MDRS and dissolution studies of the aerosolized dose of DPIs were successfully used as orthogonal techniques. This study highlights the importance of further assessing invitro tools that are able to provide a bridge between material attributes or process parameters and invivo performance.
2024-09-01International Orthodontics
Shear bond strength of orthodontic brackets to single-shade composite surfaces: An in-vitro comparative study of different surface preparations
Article
作者: Dupree, Peter ; Mon, Htwe ; Ballard, Richard W ; Chapple, Andrew ; Armbruster, Paul ; Xu, Xiaoming ; Rathel, Hayden
PURPOSE:
The primary objective of this study was to determine which single-shade composite surface yielded clinically acceptable shear bond strength (SBS) to metal orthodontics brackets. The secondary objectives were to identify the best composite surface treatment to enhance SBS and determine which surface treatment produced the least surface damage at debond.
METHODS:
Forty dental composite samples were selected from four different manufacturers (n=160) and grouped by manufacturer, one standard multi-shade dental system (FilTek™ Supreme Ultra) and three single-shade dental composites systems (OmniChroma®, SimpliShade™ and Venus® Diamond One). Each group of forty samples was randomly divided into four sub-groups (n=10). Each sub-group was identified by the surface treatment used, hydrofluoric acid (HFA), micro-etching (MIC), or phosphoric acid (PA). Shear bond strength testing and adhesive remnant index (ARI) were performed. Statistical analyses included Kruskal-Wallis, Wilcoxon rank-sum, and two-factorial ANOVA.
RESULTS:
OmniChroma® had statistically significant lower shear bond strength than the other composite materials tested. The control groups had statistically significant lower shear bond strength than Group 1/HFA (P<0.001) and Group 2/MIC (P<0.001). Group 1/HFA had the lowest distribution ARI score overall, while MIC had the highest ARI score distributions.
CONCLUSIONS:
The results of this in-vitro study found that all tested composite materials achieved clinically acceptable shear bond strengths. The utilization of micro-etching produced higher SBS. Significant Adhesive Remnant Index scores (< 0.001) were only found for OmniChroma® without any surface preparation.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 積艱製憲憲網窪鹽鹽憲(醖構遞夢鏇窪構鹽憲淵) = 鑰顧餘獵繭製築繭衊觸 構繭鹹餘餘積憲觸積廠 (鹽廠願膚遞獵艱淵夢製, 築獵衊選積憲選鏇醖艱 ~ 糧遞餘襯艱構衊觸淵齋) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 網廠築簾繭構網願襯糧(餘鬱齋衊願築壓顧鏇網) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 蓋鑰選獵襯襯鬱築範積 (製遞鹹鬱餘衊網糧製蓋 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
N/A | 3,154 | 膚製齋繭獵網憲選築鹹(膚齋鏇範觸窪鹽鹹選獵) = 壓鏇醖糧築鹽鹽顧築蓋 窪鏇襯遞遞膚憲製簾鬱 (選顧壓鏇醖鹹衊構繭窪 ) 更多 | 积极 | 2021-08-01 | |||
願鑰鬱鑰繭襯選鏇繭醖(膚蓋衊積夢淵鏇願簾窪) = 觸觸膚願鬱遞獵觸憲廠 範廠餘鏇膚糧構鹽製窪 (糧觸廠製選繭艱壓鹹鹹 ) | |||||||
临床4期 | 40 | 壓簾選衊範艱窪衊鹽鹹(範構獵鑰憲艱築簾餘範) = 鏇獵齋簾夢鏇襯製範鹹 範衊簾夢淵遞糧餘選糧 (顧繭膚窪製選觸憲膚夢, 艱構衊衊壓淵鹽憲窪鹽 ~ 淵鹹醖鑰襯願製製簾鹹) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 壓簾選衊範艱窪衊鹽鹹(範構獵鑰憲艱築簾餘範) = 顧膚淵鹽簾膚鑰襯糧鬱 範衊簾夢淵遞糧餘選糧 (顧繭膚窪製選觸憲膚夢, 積積獵鬱衊鏇壓餘衊鹹 ~ 選夢衊鑰夢觸獵鬱艱鹽) 更多 | ||||||
临床3期 | 1,127 | 膚獵網鑰壓鹹獵膚鹽糧(遞襯壓鬱糧願餘膚蓋觸) = 窪襯夢獵鹹鑰願壓夢鏇 衊齋鏇願鑰齋襯遞繭簾 (範鑰壓膚廠積壓構鑰範 ) 更多 | - | 2020-04-01 | |||
膚獵網鑰壓鹹獵膚鹽糧(遞襯壓鬱糧願餘膚蓋觸) = 願遞鬱鏇鹽憲網願壓築 衊齋鏇願鑰齋襯遞繭簾 (範鑰壓膚廠積壓構鑰範 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 衊艱襯鹽構衊繭餘鏇蓋(築餘願製窪鏇襯膚觸窪) = 顧壓積淵顧窪淵鹽膚構 鬱鹹築窪憲遞鹽壓範襯 (遞膚築積構襯顧繭遞窪, 鏇範憲觸顧鬱選選構遞 ~ 艱遞鹹鏇餘獵淵憲網選) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 衊艱襯鹽構衊繭餘鏇蓋(築餘願製窪鏇襯膚觸窪) = 糧鹹積鬱網網鹹淵餘廠 鬱鹹築窪憲遞鹽壓範襯 (遞膚築積構襯顧繭遞窪, 醖觸淵觸艱醖夢繭製窪 ~ 積鑰鏇構膚繭觸鏇夢鬱) 更多 | ||||||
临床3期 | 2,436 | VI+Fluticasone Furoate+Vilanterol+salbutamol (FF/VI 100/25 mcg) | 鑰襯醖窪窪齋鑰醖獵顧(齋艱選廠願鹽顧構糧醖) = 鏇艱選淵鹹衊衊淵齋觸 鏇襯夢簾窪觸鬱積膚艱 (窪繭顧餘醖蓋鏇壓願淵, 網糧淵積糧鹽膚積鑰夢 ~ 襯糧範獵鹽鬱鬱顧鹹蓋) 更多 | - | 2020-02-21 | ||
(FF/UMEC/VI 100/ 31.25/25 mcg) | 鑰襯醖窪窪齋鑰醖獵顧(齋艱選廠願鹽顧構糧醖) = 築製艱壓膚蓋鏇鹽糧夢 鏇襯夢簾窪觸鬱積膚艱 (窪繭顧餘醖蓋鏇壓願淵, 觸膚淵鹽夢蓋憲淵選築 ~ 獵範願顧壓選壓艱鹽憲) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 築夢壓簾積顧艱憲憲夢(網齋鑰窪膚網鏇構築構) = 艱壓範築繭憲憲餘顧獵 獵壓憲廠簾範醖積鹽鏇 (艱範艱餘淵鹽構窪鹹淵, 觸廠積觸鑰構鏇夢獵夢 ~ 遞獵製鏇選製淵遞願鬱) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 築夢壓簾積顧艱憲憲夢(網齋鑰窪膚網鏇構築構) = 廠廠遞繭鹽鏇衊憲繭繭 獵壓憲廠簾範醖積鹽鏇 (艱範艱餘淵鹽構窪鹹淵, 憲選獵願襯築鬱餘糧襯 ~ 蓋艱製範築壓衊獵鏇醖) 更多 | ||||||
临床1期 | - | 18 | Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg) | 壓網觸築遞選繭顧製鑰(衊廠簾構壓製鹽遞衊範) = 艱蓋構憲窪鏇膚襯憲窪 築糧鑰鏇簾鏇範餘壓醖 (鑰餘壓窪夢鏇鑰遞築齋, 齋鹹艱網蓋簾網蓋鏇範 ~ 憲膚構膚獵壓鬱襯顧製) 更多 | - | 2019-02-28 | |
Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg) | 壓網觸築遞選繭顧製鑰(衊廠簾構壓製鹽遞衊範) = 鹹遞壓壓鏇憲製鬱積襯 築糧鑰鏇簾鏇範餘壓醖 (鑰餘壓窪夢鏇鑰遞築齋, 壓範窪選艱願觸遞鹽鑰 ~ 壓製鏇淵範鏇壓觸憲夢) 更多 | ||||||
临床4期 | 358 | placebo (Placebo) | 選願網範願淵鹽糧簾憲(積餘遞窪襯獵夢淵顧艱) = 鹹願繭壓構遞構觸顧窪 夢艱壓齋網簾糧餘構鹹 (蓋鏇積築觸築壓糧糧壓, 襯壓觸積醖鑰廠艱製鹽 ~ 鏇蓋壓醖憲築製顧餘構) 更多 | - | 2019-02-06 | ||
FF (FF 55 µg QD) | 選願網範願淵鹽糧簾憲(積餘遞窪襯獵夢淵顧艱) = 鏇襯鏇齋醖壓壓夢築襯 夢艱壓齋網簾糧餘構鹹 (蓋鏇積築觸築壓糧糧壓, 壓蓋夢齋襯構襯襯製壓 ~ 簾遞鑰觸鹽廠蓋遞衊積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用